SEC Form 4 · accession 0001470831-26-000633
BridgeBio Pharma, Inc. · BBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles J Homcy
Director
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 6:06 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001743881
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 22, 2026 | A | 3,990 | $0.00 | A | 919,876 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $68.92 | Jun 22, 2026 | A | 5,277 | A | — | Jun 21, 2036 | Common Stock | 5,277 | 5,277 | D |
Explanation of responses
- F1Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
- F2Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F3The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.